Crown Marketing Reviews Licensing Technology for Nutraceutical and Supplement Market

Crown Marketing Reviews Licensing Technology for Nutraceutical and Supplement 
CHAPEL HILL, NC -- (Marketwire) -- 01/24/13 --  Crown Marketing
(OTCQB: CWNM) is pleased to announce that it is in discussions to
grant non-exclusive licenses of its Controlled Drug Delivery
Technology (CDDT) to Nutraceutical and Supplement Companies.  
"It's a good fit with nutraceuticals in that it can increase the
bio-availability of many of the compounds currently in use," said
Chris Francis, Director of Business Development. "We are able to
control the release with respect to amount dosed and the amount of
time it is released into the body." He continued, "This technology
will give Nutraceutical companies the ability to differentiate
themselves from the competition, and thereby increase their sales and
According to a study from Transparency Market Research, the global
nutraceutical product market reached 142.1 billion in 2011 and is
expected to reach 204.8 billion by 2017, growing at a CAGR of 6.3%
from 2012 to 2017.  
About The Company: 
Crown's Controlled Drug Delivery Technology (CDDT) is a novel
controlled-release technology, harnessing the principles diffusion
through precise mathematical formulas.
 The spectrum and reliability
of pharmacokinetic profiles achievable with this technology is
superior to currently marketed formulations. Its simple design allows
for a high level of flexibility in matching chronotherapeutic
requirements. Cost-efficiencies in the commercial manufacturing
process, when compared to other drug delivery technologies, may
constitute its most important competitive advantage. 
The objective of intelligent drug delivery design amounts to
maximizing the percent of the time drug plasma levels are within the
therapeutic range and avoiding patient exposure to potentially toxic
(High) or sub-therapeutic (Low) levels.  
Crown's cost-effective application of controlled delivery
technologies will play a major role in the expansion of the
pharmaceutical, OTC and nutraceuticals industry through our ability
to improve on the performance of immediate release products in a
manner tangible to manufacturers and consumers.  
More information can be found at: 
This release may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements contained in this release that are not historical facts
may be deemed to be forward-looking statements. Investors are
cautioned that forward-looking statements are inherently uncertain.
Actual performance and results may differ materially from that
projected or suggested herein due to certain risks and uncertainties
including, without limitation, ability to obtain financing and
regulatory and shareholder approvals for anticipated actions. 
Charles Van Der Ross
Press spacebar to pause and continue. Press esc to stop.